BioLineRx Has Dosed the First GLIX1 Patient, but Value Still Waits for Data and Funding
BioLineRx reported on April 28 that the first patient was dosed in the Phase 1/2a GLIX1 study for GBM. That is a real clinical step, but not a revenue event: the next test is safety, dose selection, enrollment pace and funding capacity through the 2027 data point.
BioLineRx reported on April 28 that the first patient was dosed in the Phase 1/2a study of GLIX1 for GBM (glioblastoma, an aggressive brain cancer). This is not proof of efficacy, not a shortcut to revenue, and not an immediate income-statement event. It moves GLIX1 from a clinic-ready promise into a stage measured through patients, safety and data.
That distinction matters after BioLineRx shifted APHEXDA commercialization to Ayrmid and Gloria and returned to a leaner royalty-and-development model. 2025 revenue fell to $1.2 million, all from Ayrmid royalties, while operating cash flow used $8.1 million. GLIX1 can bring the clinical story back to the center, but first it adds cash consumption and funding dependence.
The Trial Has Reached Patients, but Not Yet Efficacy Data
The April 28 update adds one thing that was not present on March 26: not just trial initiation, but actual treatment of the first patient. The first patient was dosed at NYU Langone Health, and Northwestern University and Moffitt Cancer Center are also expected to participate. For a first-in-human trial, that is an execution milestone: the first site has already moved a patient into the study.
The trial is still at the beginning. Phase 1/2a (safety and dose-finding with an early efficacy expansion) starts with a Phase 1 dose-escalation part in which up to 30 patients with recurrent and progressive GBM and other high-grade gliomas will receive daily GLIX1 monotherapy. The objective is to establish a maximum tolerated dose or recommended dose based on safety, PK/PD (body exposure and biological response) and preliminary efficacy signals. Data from the Phase 1 part are expected in the first half of 2027.
| Timing | What changed | What is still missing |
|---|---|---|
| March 26 | The clinical trial was initiated | No patient had yet been dosed |
| April 28 | The first patient was dosed with GLIX1 | No safety or efficacy data yet |
| First half of 2027 | Phase 1 data are expected | Dose, safety and a clinical signal need to support expansion |
GLIX1 Adds a Clinical Asset and a Funding Requirement
GLIX1 is an oral small molecule designed to activate TET2 (an enzyme involved in DNA methylation control) and drive selective DNA damage in cancer cells. In pre-human models it showed anti-tumor activity, blood-brain-barrier penetration and a safety profile that supported clinical entry. Those facts are the scientific basis for a trial, not clinical proof.
The economics around GLIX1 matter as much as the science. BioLineRx owns 40% of Tetragon, the company formed with Hemispherian to develop GLIX1, while Hemispherian owns 60%. BioLineRx manages the activity and holds a deciding vote, but its 40% stake is conditional. The company committed to invest $5.0 million in Tetragon within 36 months from late September 2025, and had invested $1.2 million by the end of 2025. If the threshold is not funded on time, Hemispherian can repurchase a pro rata portion of BioLineRx’s Tetragon shares for nominal consideration.
There is another cost layer: Tetragon is expected to pay Hemispherian a monthly advisory fee of $80,000 for 24 months or until the collaboration ends. The balance sheet records a $6.0 million intangible asset for GLIX1, but it was recorded against non-controlling interests in the same amount. First-patient dosing improves the probability of clinical progress, but does not turn accounting value into accessible cash.
The Cash Balance Is Expected to Reach the Data Point, but With Limited Room for Error
The relevant all-in cash picture is cash and deposits against actual uses: operations, debt repayment, lease payments and new equity capital. BioLineRx ended 2025 with $20.9 million in cash, cash equivalents and short-term deposits, and management expects that balance to meet capital requirements into the first half of 2027. That is also when GLIX1 Phase 1 data are expected.
Relying on that runway alone misses the friction. In 2025 the company used $8.1 million in operating activities, repaid $4.5 million of the BlackRock loan and paid $0.5 million for leases. It funded the gap with equity: a January registered direct offering with $10.0 million of gross proceeds and $8.9 million net, plus $5.0 million of net proceeds from ADS sales through the ATM (at-the-market share-sale) program. Net financing cash flow was $8.9 million after loan and lease repayments.
The BlackRock loan is still part of the background. At the end of 2025, the balance sheet included $4.5 million of current loan maturities and another $4.5 million of long-term loan, with scheduled repayment through December 1, 2027. The agreement requires a $4.0 million minimum cash balance, and 10% of future license milestones through that date must repay principal. Any enrollment delay or more expensive GLIX1 expansion can quickly become a funding question.
The Next Read Depends on What Appears Before 2027
The April 28 update improves visibility on GLIX1’s clinical path, but not yet the quality of BioLineRx’s revenue base. The next stage depends on enrollment pace, safety that supports a recommended dose, and activity signals that justify moving into Phase 2a expansion.
Until then, GLIX1 is mostly a clinical option with a funding cost. The fair counterpoint is that first-patient dosing lowers execution risk and moves the company closer to a data point that could improve financing terms or support a partnership. If the data are delayed or fail to show a clear clinical signal, BioLineRx will remain with an interesting asset, development expenses, and high dependence on royalties, milestones and the capital markets.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.